3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
50
Lung Neoplasms
25
Neoplasms
7
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Neoplasm Metastasis
6
Colorectal Neoplasms
5
Pancreatic Neoplasms
4
Mesothelioma, Malignant
3
Melanoma
3
Colonic Neoplasms
3
Carcinoma
3
Squamous Cell Carcinoma of Head and Neck
2
Rectal Neoplasms
2
Ovarian Neoplasms
2
Non-squamous Non-small Cell Lung Cancer
2
Neoplasms by Site
2
Mesothelioma
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Adenocarcinoma of Lung
2
Vaccinia
1
Uterine Cervical Neoplasms
1
Thoracic Neoplasms
1
Solitary Fibrous Tumor, Pleural
1
Solid Tumors
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Interventions
durvalumab
2
ruxolitinib
1
repotrectinib
1
cemiplimab
1
atezolizumab
1
Pemetrexed
1
Nivolumab
1
Immunotherapy
1
Docetaxel
1
Cisplatin
1
CPI-0610
1
Biopsy
1
Bevacizumab
1
ALT-803
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
Pemetrexed
×
30 days
×
Clear all
NCT06463665
2026-06-04
VIRO-25
Genelux Corporation
Phase 2
Recruiting
142 enrolled